| Earnings Per Share (EPS): Change in analysts' estimates |
|
|
|
| Turnover: Change in analysts' estimates |
|
|
|
|
|
|
Merck sees up to $7 billion in sales of COVID-19 drug through end of 2022 |
|
MERCK AND COMPANY
Leader in oncology, modest valuation |
Next year EPS consensus revisions
Revenue consensus revisions
Next year Revenue consensus revisions
|
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
